 SAN JOSE, Calif., April 19, 2021 PRNewswire -- Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration US FDA has requested additional information regarding its Chimeric Antigen Receptor-T cell therapy CAR-T being developed in partnership with Moffitt Cancer Center MCC. 